Our latest articles
Asco 2023 – Novocure sinks as Lunar’s limitations become clear
A pivotal lung cancer hit in an outdated setting means the company might struggle with adoption.
Asco 2023 – Dizal heralds a “super-Tagrisso”
China’s Dizal, an unexpected targeted therapy star of Asco 2021, is back with even more impressive data.
Asco 2023 – early first-line lung cancer data mined for datopotamab gold
The search is on for signals in front-line use, where Daiichi Sankyo and Astrazeneca have already bet big with the Trop2-targeted project.
Setrusumab’s second attempt shows promise
Ultragenyx and Mereo celebrate a mid-stage biomarker win, but have much to do in phase 3.
Asco 2023 – Enhertu hits with pan approach
Strong data prompt talk of a tumour-agnostic approval, but regulators could prove reluctant in the broad Her2 setting.
Asco 2023 – Bicara eyes head and neck niche
Impressive data in HPV-negative disease, potentially beating Keytruda, has the private group making pivotal plans.
Asco 2023 – liver tox casts a pall over Servier’s Indigo readout
Vorasidenib, potentially the first targeted therapy for low-grade glioma, comes at a toxicity price.
Asco 2023 – Roche sees Morpheus and takes the red pill
The company’s Tigit data are strong enough for a phase 3 trial to be launched, Asco learns.
Asco 2023 – Trop2 could validate Merck’s savvy deal with Kelun
In Trop2 Merck & Co might have got itself an ADC at least as good as Gilead and Astra/Daiichi’s leaders, for a fraction of the price.
Asco 2023 – deep and early responses lift hopes at Effector
New data with a novel RNA translation regulator gave the stock a pre-Asco boost, but the micro-cap company needs to keep the momentum going.